期刊
BIOENGINEERING-BASEL
卷 7, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/bioengineering7030097
关键词
tissue engineering; cell transplantation; stem cells; satellite cells; induced pluripotent stem cells; volumetric muscle loss
资金
- US National Institutes of Health [R01 HL127113, R01 HL142718]
- National Science Foundation [1829534]
- Department of Veterans Affairs [1I01BX004259]
- Alliance for Regenerative Rehabilitation Research & Training (AR3T) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health [P2CHD086843]
- National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health [P2CHD086843]
- National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health [P2CHD086843]
Extensive damage to skeletal muscle tissue due to volumetric muscle loss (VML) is beyond the inherent regenerative capacity of the body, and results in permanent functional debilitation. Current clinical treatments fail to fully restore native muscle function. Recently, cell-based therapies have emerged as a promising approach to promote skeletal muscle regeneration following injury and/or disease. Stem cell populations, such as muscle stem cells, mesenchymal stem cells and induced pluripotent stem cells (iPSCs), have shown a promising capacity for muscle differentiation. Support cells, such as endothelial cells, nerve cells or immune cells, play a pivotal role in providing paracrine signaling cues for myogenesis, along with modulating the processes of inflammation, angiogenesis and innervation. The efficacy of cell therapies relies on the provision of instructive microenvironmental cues and appropriate intercellular interactions. This review describes the recent developments of cell-based therapies for the treatment of VML, with a focus on preclinical testing and future trends in the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据